Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79OV, and APGOT-OV9) phase 2/3 study (SGO 2025) - Feb 8, 2025 - Abstract #922978; Pres time: Mar 15, 2025; 03:40 PM - 03:46 PM; Location: 4E; No abstract available
Clinical • Late-breaking abstract • P2/3 data • Oncology • Ovarian Cancer • Solid Tumor
|